Duke names several hormone delivery forms. A Durham consultation can address the question, but the public menu does not identify a prescription or pharmacy product.
A person asking Duke Health about a patch is bringing a more specific question than someone asking generally about menopause care. The website can help locate a clinical service, but it cannot say whether that person needs estradiol, which preparation would be proposed or what the dispensing pharmacy would provide. Those are different stages of the same conversation.
We reviewed Duke’s service and Durham clinic information on September 28, 2026, alongside federal medication references. Form & Route examines what those pages establish and what still requires a conversation with the care team. This is an assessment of published information; no appointment, prescription or pharmacy transaction was tested.
Duke’s menopause service describes hormone therapy as one possible approach and lists pills, patches and other forms such as gels, sprays, rings, creams and vaginal tablets. It also describes estrogen alone and estrogen with progesterone. This is a broad treatment description; it does not give a verified Duke estradiol formulary.
The first useful distinction is between a category the service discusses and a product a clinician has selected. The form-questions guide helps preserve that distinction. A patch appearing in an institutional overview does not establish a particular brand, strength or supply, nor does the same list show that every form is available from every Duke clinician.
The Patterson Place clinic record connects menopause assessment with Duke Women’s Health Associates in Durham. Its menopause practitioner asks about the effect of symptoms and considers whether further evaluation or treatment might help. This provides a clinical entry point for a form question, rather than a link to buy a named medicine.
That office also handles other gynecological care. When requesting an appointment, the unresolved administrative detail is which visit addresses a current prescription or a possible new treatment. The UCLA review describes another named-program intake process. Comparing the two is about the receiving service and its preparation, not treating a hospital network as an online prescription storefront.
MedlinePlus’s estradiol patch information distinguishes indications and gives product-specific information rather than presenting all patches as one identical medicine. That national reference does not establish which products Duke prescribes. It shows why the exact preparation and clinical purpose remain necessary even after the word patch has appeared in a discussion.
A useful question for the clinician is what the proposed medicine is intended to address and why that form is being considered. The answer should accompany the name on the prescription. This review does not select a patch, compare strengths or provide a switching schedule. A preference about convenience is information to discuss, not enough evidence to choose treatment.
Duke’s evaluation description allows for consideration of conditions beyond menopause. An existing medication record can therefore contribute more than the name of a hormone. The FDA medication-list page describes recording prescription and nonprescription products, strengths and reasons for use, along with other relevant details.
Our medication-list review guide turns that into questions for a professional conversation. The aim is an accurate account of what is actually being taken, not an attempt to decide which combinations are compatible. A clinician receiving a list still needs to interpret it. Uploading information does not establish that a medication review has already occurred.
Patterson Place describes My Duke Health as a way to request refills and communicate with the care team. The clinic page does not describe a guaranteed refill approval or a particular dispensing pharmacy for menopause prescriptions. A request, a prescribing decision and a filled medicine remain separate records.
The label-and-pharmacy guide can help identify what to clarify when those records differ. For example, a person can ask which professional should explain a changed product name or an unclear route. That question does not presume an error or authorize a substitution. It keeps responsibility visible between the clinician’s plan and the medicine eventually supplied.
The clinic’s insurance information tells patients to check the specific provider or location with their insurer and distinguishes participation from patient cost sharing. It does not give a complete price for an estradiol assessment or establish prescription coverage. A consultation charge cannot stand in for the later pharmacy bill.
The Mount Sinai review explores another system where the entity providing care matters to the financial record. For Duke, an estimate would need to identify the proposed visit and any separately charged services. Until an actual prescription exists, its product, quantity and price are unknown. The reviewed pages do not support a monthly or annual estradiol-package calculation.
The Duke service record supports a conversation about menopause treatment, while the clinic record locates that conversation in regional gynecology care. Neither proves that a reader can receive remote treatment nationwide. The open questions concern who assesses the symptoms, who authorizes a prescription and who answers questions about the dispensed product.
That is the appropriate level for this provider comparison. Duke’s broad list of forms should become more specific only through an actual clinical and pharmacy record. An institutional name does not settle the route, the exact medicine or the follow-up arrangement. This review leaves those decisions unresolved and supplies linked questions for the professionals responsible for them.
Follow the source
Provider pages describe services. Medical and regulatory sources supply clinical context. None of these references substitutes for a personal assessment.